EGFR、COX-2的表达以及MVD与早期非小细胞肺癌预后的相关性

EGFR,COX-2 Expression Status and Microvessel Density Correlated to Prognosis in Early Stage Non-small Cell Lung Cancer

目的研究EGFR(表皮生长因子受体)、COX2(环氧合酶2)和MVD(微血管密度)与早期非小细胞肺癌(NSCLC)的无病生存期之间的关系。方法回顾性分析36例NSCLC术后患者的病理标本,用免疫组化的方法检测其EGFR,COX2和MVD(以CD34特异标记)的表达情况。结果EGFR和COX2的阳性表达率分别为44%和53%。这个指标均与无病生存期无显著的关系。MVD平均值为65.3,标准差为17.6,以平均值界分成高表达和低表达组。MVD高表达有导致更短的无病生存期的趋势(P=0.08)。EGFR-/COX2+/MVD高表达的早期NSCLC的无病生存期显著降低(P=0.04)。结论COX2和MVD高表达和EGFR低表达的早期NSCLC可能是高危人群,将需要更积极的辅助化疗。

Objective We studied the association between the expression of epidermal growth factor receptor（EGFR）, Cyclooxygenase-2 （COX-2）, microvessel density（MVD） and disease free survival in early stage non-small cell lung cancer （NSCLC）. Methods Thirty-six patients with NSCLC undergoing complete surgical resection were evaluated retrospectively. Tumo（ specimens were stained for EGFR, COX-2 and specific MVD marker（CD34） by Immunohistochemistry. Results EGFR and COX-2 over expressions were demonstrated in 44% and 53% of tumors. Both of markers alone had any significant impact on disease free survival. The mean of MVD as assessed by CD34 was 65.3 （SD 17. 6）, which was chosen as the cutoff point. High MVD had a trend to shorten disease free survival（P = 0.08）. EGFR - / COX-2 ＋ / high MVD proved to have a poor disease free survival（P = 0. 04）. Conclusion Hih risk patients with early stage NSCLC may be identified When COX-2 and MVD are overexpressed without a concomitant over express of EGFR, which may need further adjuvant chemotherapy.